GCP guidelines for high-risk medical devices in South Korea mandate comprehensive study designs with robust preclinical data and extensive clinical trials. They require informed consent from participants, thorough monitoring of safety and efficacy, detailed reporting of adverse events, and regular data audits to ensure compliance with ethical standards and regulatory requirements throughout the trial.
